Investors Research Corp Takes Position in AstraZeneca plc (AZN)
Investors Research Corp purchased a new position in shares of AstraZeneca plc (NYSE:AZN) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 7,966 shares of the company’s stock, valued at approximately $276,000.
Several other institutional investors have also recently added to or reduced their stakes in AZN. American International Group Inc. bought a new position in shares of AstraZeneca during the fourth quarter worth about $1,976,000. Russell Investments Group Ltd. grew its position in shares of AstraZeneca by 198.9% during the third quarter. Russell Investments Group Ltd. now owns 1,856,140 shares of the company’s stock worth $62,883,000 after acquiring an additional 1,235,239 shares during the last quarter. Hardman Johnston Global Advisors LLC bought a new position in shares of AstraZeneca during the fourth quarter worth about $35,125,000. Sector Gamma AS bought a new position in shares of AstraZeneca during the third quarter worth about $25,094,000. Finally, Arrowstreet Capital Limited Partnership bought a new position in shares of AstraZeneca during the fourth quarter worth about $25,455,000. Institutional investors and hedge funds own 15.13% of the company’s stock.
AstraZeneca plc (NYSE AZN) opened at $33.16 on Monday. The stock has a market cap of $83,987.32, a PE ratio of 13.99, a P/E/G ratio of 1.98 and a beta of 0.71. The company has a debt-to-equity ratio of 0.93, a current ratio of 0.80 and a quick ratio of 0.62. AstraZeneca plc has a 12-month low of $28.43 and a 12-month high of $36.70.
The firm also recently declared a semiannual dividend, which will be paid on Monday, March 19th. Shareholders of record on Friday, February 16th will be issued a $0.95 dividend. This represents a yield of 5.62%. The ex-dividend date is Thursday, February 15th. AstraZeneca’s payout ratio is 57.81%.
Several equities analysts have recently commented on the stock. BMO Capital Markets restated a “buy” rating and set a $38.00 price target on shares of AstraZeneca in a research report on Friday, January 26th. Zacks Investment Research upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Monday, January 22nd. ValuEngine upgraded shares of AstraZeneca from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 3rd. Leerink Swann reiterated a “market perform” rating and issued a $36.00 target price (up previously from $33.00) on shares of AstraZeneca in a research report on Thursday, January 18th. Finally, Sanford C. Bernstein increased their target price on shares of AstraZeneca from $40.00 to $42.00 and gave the company an “outperform” rating in a research report on Monday, February 5th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $36.26.
ILLEGAL ACTIVITY WARNING: This news story was reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.dailypolitical.com/2018/03/05/investors-research-corp-takes-position-in-astrazeneca-plc-azn.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.